Early clinical results support Da Vinci FS laser

Article

Swiss firm, Ziemer Ophthalmic Systems took advantage of the ESCRS congress to reveal its femtosecond laser Da Vinci to the ophthalmic community.

Swiss firm, Ziemer Ophthalmic Systems took advantage of the ESCRS congress to reveal its femtosecond laser Da Vinci to the ophthalmic community.

During wet lab demonstrations, ophthalmologists took the opportunity to sample the Da Vinci systems, the first series of which are making their way off the assembly line and into more extensive clinical testing.

Following an initial series of regular clinical applications, performed in collaboration with refractive surgeons in Switzerland, Germany and the UK, LASIK flaps were created in the corneas of LASIK patients, followed by standard excimer laser ablation.

According to the surgeons, the Femto-LASIK procedure was uneventful and yielded satisfactory outcomes with target refraction achieved and no complications reported. At two-week follow-up, there were no apparent signs of laser-induced complications.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.